Hanmi Science Co., Ltd.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Hanmi Science Co., Ltd. - overview
Established
1973
Location
Seoul, -, South Korea
Primary Industry
Medical Devices & Equipment
About
Founded in 1973, and based in South Korea, Hanmi Science Co. , Ltd. is a holding company that manages subsidiaries that are involved in the development of pharmaceutical products, the provision of health supplement foods, and the manufacturing of medical devices. In May 2023, La Defense Partners agreed to invest KRW 320 billion in Hanmi Science.
As of 2023, the company is led by its CEO Youngsook Song. Hanmi Science offers a wide range of healthy functional food including iHealth Lutein A+, iHealth Lutein Plus, Live Lactobacillus Probiotics, Hanmi RT Omega 3, Immune Red Ginseng Extract, Oscor N-Acetylglucosamine, River Khan Milk Thistle, Hwassak, Vitamin D 4000IU, Multivitamin Mineral Max, Vitamin D Kids, and 1000IU Immune Postbiotics Kids. It also provides medical equipment including syringes.
Current Investors
La Defense Partners
Primary Industry
Medical Devices & Equipment
Sub Industries
Health Foods & Nutritional Supplements, Healthcare IT, Diagnostic Equipment, Medical Supplies, Surgical Devices, Pharmaceutical Research & Development, Medical Software
Website
www.hanmiscience.co.kr
Verticals
HealthTech, Manufacturing
Company Stage
Mature - Growth Capital
Total Amount Raised
Subscriber access only
Hanmi Science Co., Ltd. - timeline of key events
Hanmi Science Co., Ltd. - financials
| Fiscal Year Ended | Dec 31, 2011 | Dec 31, 2012 | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 | Dec 31, 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | 17,345,555,614 | 20,179,239,149 | 220,395,816,008 | 532,886,463,400 | 776,628,551,410 | 665,284,666,051 | 652,324,367,919 | 707,995,356,123 | 816,618,823,610 | 857,383,419,139 | 950,164,817,343 | 1,046,054,210,838 | - | - | - |
| % Revenue Growth (YoY) | - | 16.3% | 992.2% | 141.8% | 45.7% | (14.3%) | (1.9%) | 8.5% | 15.3% | 5.0% | 10.8% | 10.1% | - | - | - |
| EBITDA (USD) | 4,542,687,204 | 13,900,208,851 | 11,732,026,287 | 18,338,242,936 | 217,568,446,033 | 30,496,787,002 | 41,770,690,361 | 28,746,743,542 | 40,566,809,487 | 35,118,309,426 | 64,108,833,451 | 73,104,461,586 | - | - | - |
| Operating Income (USD) | 4,413,979,521 | 13,202,272,465 | 11,185,466,471 | 17,470,787,747 | 216,415,186,418 | 28,651,638,438 | 39,071,351,376 | 26,155,011,471 | 37,986,177,391 | 32,502,305,256 | 58,852,290,702 | 67,626,014,492 | - | - | - |
| Operating Margin | 25.4% | 65.4% | 5.1% | 3.3% | 27.9% | 4.3% | 6.0% | 3.7% | 4.7% | 3.8% | 6.2% | 6.5% | - | - | - |
| % EBITDA Margin | 26.2% | 68.9% | 5.3% | 3.4% | 28.0% | 4.6% | 6.4% | 4.1% | 5.0% | 4.1% | 6.7% | 7.0% | - | - | - |
| NET Income (USD) | (14,686,154,147) | 12,480,699,639 | 9,597,891,463 | 21,862,379,723 | 177,449,858,131 | 7,940,308,277 | 30,818,254,865 | 18,021,624,665 | 30,742,878,636 | 22,596,604,093 | 42,939,923,264 | 69,035,321,647 | - | - | - |
| % Net Margin | (84.7%) | 61.8% | 4.4% | 4.1% | 22.8% | 1.2% | 4.7% | 2.5% | 3.8% | 2.6% | 4.5% | 6.6% | - | - | - |
Hanmi Science Co., Ltd. - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PIPE | Completed | Hanmi Science Co., Ltd. | - | ||||||||
| PIPE | Completed | Hanmi Science Co., Ltd. | - | ||||||||
| Unspecified Round | Completed | BioApp | - | ||||||||
| Series A | Completed | Tomocube | - |
Displaying 1 - 4 of 4
Hanmi Science Co., Ltd. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.